Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Description 

The transition from childhood to adolescence and adulthood represents unique developmental periods with significant social network and interaction changes. Adolescence and early adulthood are the peak times for initiating substance use disorders (SUD), particularly tobacco, marijuana, prescription drugs, and alcohol. Medication-assisted treatment and evidence-based SUD counseling are available but underused in this vulnerable population. This presentation will be divided into four parts and will discuss the main substances used and abused by adolescents in the United States; Alcohol, Marijuana and tobacco use, opioids, and stimulants. We will discuss prevention, screening, evaluation, and referral to treatment of adolescents with or at risk for these substance use disorders. The presentation will discuss the latest evidence-based data on medication for assisted treatment and other therapies for adolescents. The discussion focuses on recognizing the best practices in preventing and treating adolescents with substance use disorders. The presentation: 1) Review the current trends in adolescent substance use. 2) Describes why adolescents are particularly vulnerable to substance use disorders. 3) Describes the risk and protective factors for adolescent substance use and will help to identify evidence-based community, school, family, and peer prevention strategies.

Please note you must complete all 4 modules in order to claim credit for this course. 

Pricing  

FREE - $0 

Learning Objectives  

• Identify current adolescent substance use disorder trends, emphasizing opioid, tobacco, alcohol, and stimulant use disorders. 
• Describe why adolescents are particularly vulnerable to substance use. 
• Describe the diagnosis of ADHD and pharmacologic treatments for ADHD with suspected or proven comorbid SUD.
• Discuss the clinical assessment, approach, and treatment available to treat opioid, tobacco, alcohol, and stimulant use disorders in the youth.  

Target Audience  

Psychiatrists

Estimated Time to Complete 

Estimated Duration: 5.0 hours  

Program Begin Date: August 28, 2023 

Program End Date: September 24, 2023  

Credit Claim End Date: November 23, 2023 

How to Earn Credit
After evaluating the program, participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (non-physicians) showing the event date and hours earned.

Continuing Education Credit
In support of improving patient care, the American Psychiatric Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
The APA designates this enduring activity for a maximum of 5 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures 

The American Psychiatric Association adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Medical Education. Any individuals in a position to control the content of a CME activity — including faculty, planners, reviewers or others — are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.  

Instructor:  

• Hector Colon-Rivera, MD, MBA, MRO. Reports no financial relationships with commercial interests.    

Planners: 

• Hector Colon-Rivera, MD, MBA, MRO. Reports no financial relationships with commercial interests.    

Accessibility for Participants with Disabilities 

The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.